Bristol-Myers Squibb CoMIL:1BMY +3.55%50 Pretax Margin % is 28.20% as of Mar. 2026, which is 49% above its 10-year median of 18.89. GuruFocus rates MIL:1BMY with a GF Score™ of 50/100 and a GF Value™ of €47.54 (Fairly Valued). The stock has 6 warning signs investors should review. Among 954 Drug Manufacturers companies, Bristol-Myers Squibb Co ranks better than 80.71% on this metric.
The historical rank and industry rank for Bristol-Myers Squibb Co's Pretax Margin % or its related term are showing as below:
MIL:1BMY'
s Pretax Margin % Range Over the Past 10 Years
Min: -17.35 Med: 18.89 Max: 30.45
Current: 19.8
MIL:1BMY's Pretax Margin % is ranked better than 80.71% of 954
companies
in the Drug Manufacturers industry
Industry Median: 7.295
vs MIL:1BMY: 19.80
Bristol-Myers Squibb Co (MIL:1BMY) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Bristol-Myers Squibb Co Pretax Margin % Related Terms
Bristol-Myers Squibb Co Pretax Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MIL:1BMY vs PFE, GILD, AMGN: Pretax Margin % Comparison
For the Drug Manufacturers - General subindustry, Bristol-Myers Squibb Co's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bristol-Myers Squibb Co Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bristol-Myers Squibb Co's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Bristol-Myers Squibb Co's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bristol-Myers Squibb Co (MIL:1BMY) has a Pretax Margin % of 28.20% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Bristol-Myers Squibb Co and its competitors. This is 49% above median its historical median of 18.89. According to the industry distribution chart, Bristol-Myers Squibb Co ranks #184 out of 954 companies in the Drug Manufacturers industry, placing it in the top 19.3%.
Is Bristol-Myers Squibb Co's Pretax Margin % too high?
Bristol-Myers Squibb Co's current Pretax Margin % of 28.20% is 49% above median its 10-year median of 18.89. The Drug Manufacturers industry median Pretax Margin % is 7.30. Bristol-Myers Squibb Co's value of 28.20% is 286.6% above this industry median. Based on the distribution chart, Bristol-Myers Squibb Co ranks #184 out of 954 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Bristol-Myers Squibb Co has a GF Score™ of 50/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bristol-Myers Squibb Co's Pretax Margin % compare to PFE and GILD?
According to the Drug Manufacturers industry distribution chart, Bristol-Myers Squibb Co ranks #184 out of 954 companies for Pretax Margin %. This places Bristol-Myers Squibb Co in the top 19% of its industry — outperforming the majority of peers. The industry median Pretax Margin % is 7.30. Bristol-Myers Squibb Co's value of 28.20% is 286.6% above this benchmark. While the company's 10-year median is 18.89 vs. the industry median of 7.30, Bristol-Myers Squibb Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.30, based on 954 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bristol-Myers Squibb Co's current Pretax Margin % of 28.20% is 286.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Bristol-Myers Squibb Co and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bristol-Myers Squibb Co's current Pretax Margin % is 28.20%, which is 49% above median its own 10-year median of 18.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bristol-Myers Squibb Co stock overvalued right now?
Based on GuruFocus' analysis, Bristol-Myers Squibb Co (MIL:1BMY) is currently considered Fairly Valued. The stock's GF Value™ is €47.54, compared to a current price of €50.38 — trading 6% above its estimated fair value. The current Pretax Margin % is 28.20%, which is 49% above median its 10-year median of 18.89 and 286.6% above the Drug Manufacturers industry median of 7.30. Bristol-Myers Squibb Co's overall GF Score™ is 50/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Bristol-Myers Squibb Co (MIL:1BMY), the current Pretax Margin % is 28.20% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bristol-Myers Squibb Co (MIL:1BMY) Overvalued in 2026?
Based on GuruFocus' analysis, Bristol-Myers Squibb Co stock appears to be overvalued.
The current stock price of €50.38 is trading 6% above its estimated GF Value™ of €47.54.
GuruFocus considers Bristol-Myers Squibb Co to be Fairly Valued.
Key valuation signals for MIL:1BMY:
Pretax Margin %: 28.20% (49% above median its 10-year median of 18.89)
GF Value™: €47.54 vs. price of €50.38 (6% above fair value)
Industry Position: 286.6% above the Drug Manufacturers median (#184 of 954)
No single metric tells the full story. See the MIL:1BMY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
50GF Score
Get the complete analysis for MIL:1BMY
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:1BMY has been successfully added to your 
